Only a third of patients with major depressive episodes (MDE) achieve remission after 3 months of antidepressant treatment [1] . To reduce risks, suffering and minimize costs associated with major depressive disorder (MDD), it is useful to determine criteria that may predict antidepressant efficacy. To the best of our knowledge, these criteria are scarce [2] . Thus, the prediction of response and remission in depressed patients treated with antidepressant drugs remains a challenge for clinicians.
Growing evidence suggests the implication of adult brain plasticity, especially adult hippocampal neurogenesis in antidepressant efficacy [3] [4] [5] [6] , especially pharmacogenetic studies focusing on the brain-derived neurotrophic factor (BDNF) and its receptors tyrosine kinase receptor B (TRKB) and p75 neurotrophin receptor (P75NTR) (alternatively named as NGFR or tumor necrosis factor superfamily member 16, TNFRSF16).
The BDNF is a member of the neurotrophin family [7] . The BDNF gene comprises 11 exons that span about 70 kb of chromosome 11 [8] . BDNF, initially synthesized as 32 kD precursor protein called pro-BDNF, is intra-and extracellularly cleaved to produce the mature BDNF form [9, 10] . Mature BDNF binds to TRKB receptors with high affinity [11, 12] . The BDNF/TRKB couple increases neuronal plasticity, such as neurogenesis, neurite arborization and synapto genesis. ProBDNF/P75NTR couple lead to programmed neuronal death, neurite retraction and synaptic pruning [12] .
TRKB is mainly present in the central and peripheral nervous system [13, 14] . This receptor is located on the cellular membrane and mediates the effects of BDNF through its extra-and intracellular domains. It is coded by a 24-exon gene that spans about 24 kb located on chromosome 9(q22.1) [15, 16] ization and autophosphorylation of TRKB, resulting in sequential phosphorylation in intracellular signaling pathways. The BDNF-activated TRKB signaling pathway increases neuronal plasticity, such as neurogenesis, neurite arborization and synaptogenesis. The P75NTR gene comprises six exons that span about 23 kb of chromosome 17q21-q22. P75NTR preferentially binds mature pro-BDNF. Pro-BDNF-P75NTR pathway may promote cell death in rodent neurons, oligodendrocytes and Schwann cells [17] . If co-expressed, TrkB and P75NTR work together as a receptor complex for mature BDNF. In this heterodimer, the mature BDNF seems to interact solely with the TRKB component, p75NTR acting indirectly to increase the number of high affinity binding sites for TRKB [18] .
Preclinical evidence suggests that the BDNF/TRKB pathway is involved in the pathophysiology of mood disorders and that BDNF-promoted neuronal plasticity underlies the effect of antidepressants. Indeed, in rats, stress induced decrease in BDNF mRNA expression in the hippocampus [19] . And BDNF injections in the dentate gyrus of the hippocampus lead to improvement in depressive behaviors [20] . Similarly, a chronic treatment with antidepressant restores stress-induced changes in BDNF mRNA levels in experimental animals [19, 21] . Some preclinical studies also argue for a different impact of BDNF on antidepressant efficacy depending on antidepressant drugs [22] [23] [24] . In rodents, TRKB agonists reverse antidepressant-like behaviors [25] , TRKB is activated by antidepressants [26] and the absence of this receptor in hippocampus cells decreases antidepressant efficacy [27, 28] .
Clinical studies also point out that BDNF and TRKB receptor density in the brain and BDNF concentrations are decreased in the plasma of suicidal subjects [29, 30] . Furthermore, antidepressant treatment increases BDNF levels in the hippocampus of postmortem human brains [31] . In a more recent study, in MDD patients, serum BDNF was decreased during MDE and some data suggest that antidepressants may act by normalizing the levels of serum BDNF [32, 33] .
Taking into account the growing evidence for BDNF/TRKB/P75NTR involvement in antidepressant efficacy and the need for biomarkers to guide clinical prescription of antidepressant drugs, we propose an extensive review of the literature about the effects of polymorphisms of the BDNF/TRKB/P75NTR signaling pathway on antidepressants efficacy in depressed patients.
Methods
We reviewed the literature by an extensive PUBMED search of studies published until December 2014.
First, we used PUBMED SNP to identify published SNPs for the BDNF, TRKB and PNTR75 genes. Only SNP studies involving antidepressant drugs were selected for this review. Second, we checked the references of all included studies to identify supplementary data. Third, we screened each SNP as keyword 'rs…' in PUBMED to identify further studies. Finally, to be included in this review, studies had to be clinical prospective studies, with clinical assessment at baseline and at the end of the follow-up period and of patients with a diagnosis of MDE (DSM criteria) either MDD or bipolar and treated with antidepressant drugs (all marketed antidepressant drugs could be included).
The screening of studies was performed independently by two investigators (R Colle and S Martin for BDNF/P75NTR and E Deflesselle and S Martin for TRKB). In case of disagreement, the relevance of the study was assessed consensually by both investigators. Thus, 37 studies were initially selected and four studies were excluded, two because of the absence of pharmaco logical treatment, another because it did not focus on antidepressant efficacy and the last one for statistical methodological limitations.
Overall, five genome-wide association studies (GWAS) (including one meta-analysis) and 30 pharmaco genetic association studies (methodology in Table 1 ) were included in this review.
Levels of evidence for each SNP were estimated individually based on the 'clinical annotation level of evidence' of PharmGKB [63] described in Supplementary Table 1 (see online at: www.futuremedicine.com/doi/suppl/10.2217/pgs.15.56). Extrapolations of this assessment scale were also proposed to estimate the level of evidence for haplotype associations.
Results

GWAS
We identified four GWAS studies: Uher et al., 2010 [64] (GENDEP, n = 706), Ising et al., 2009 [65] (MARS, n = 339 + German replication sample, n = 361), Garriock et al., 2010 [66] (STAR*D, n = 1948), Ji et al., 2013 [67] (PGRN-AMPS, n = 529). None of these studies reported SNP of BDNF/TRKB/P75NTR associated with antidepressant efficacy. Accordingly, a meta-analysis of three GWAS (STAR*D, GENDEP and MARS) [68] 
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cacy. The 47 others were explored: a significant association was shown for eight of them whereas there is no reported association for the 39 others. Among the 37 which were never explored for antidepressant efficacy, three were located in an exonic region and concern missense mutations (rs1048218, rs1048220 and rs1048221), 15 were localized in intronic regions (rs11030107, rs11030108, rs11030118, rs11030119, rs12291063, rs12291186, rs16917234, rs1967554, rs2030323, rs2049045, rs2049046, rs56164415, rs6484320, rs7127507, rs7934165), one was in 5′-UTR (rs28383487) region, one in 3′-UTR (rs11030100) and, for 17 SNPs, the locations were unknown (rs10835187, rs11030064, rs1157659, rs1387145, rs1519480, rs2203877, rs2352802, rs2883187, rs3750934, rs3763965, rs4074134, rs4923461, rs4923463, rs7481311, rs8192466, rs972096, rs988712). These 47 SNPs were extracted from 28 association studies, were assessed for their association with anti depressant efficacy in MDD (Table 1) . Historically, the first studies assessed the functional Val66Met polymorphism. Other ones investigated other gene locations with a systematic approach. For the first time in 2009, Licinio et al., [41] investigated together exonic, intronic, 3′-UTR and 5′-UTR region with a complete sequencing approach. Kocabas et al., 2011 [49] focused on 3′-UTR and 5′-UTR regions.
Only the study of Licinio et al., 2009 was a randomized double-blind controlled trial [41] . Since MDE occurs mainly in MDD but also in bipolar disorders, and because response to antidepressants may differ between MDD and bipolar disorder, this point was examined carefully: 12 studies had explicit exclusion criteria for bipolar disorders. Nine studies focused on MDD but did not exclude explicitly bipolar disorders. Bipolar disorders were included in four studies (frequency: 11-40%). Ethnicity was also heterogeneous: 13 studies focused on Asian patients and 14 on Caucasians patients. 8 studies focused on selective serotonin reuptake inhibitor (SSRI), one on venlafaxine (SNRI) and two on mirtazapine. In the others, several classes of antidepressant drugs were assessed. Except six studies with a duration longer than 12 weeks, most studies were short term ones (4-8 weeks).
Polymorphisms with no reported association
We show the 39 SNPs with no association with antidepressant efficacy in Supplementary Table 2. Polymorphisms with a reported positive association Table 2 shows the eight SNPs with a reported association with antidepressant efficacy (level of evidence of 3). The most studied BDNF polymorphism is the Val66Met (rs6265) (Valine is changed by Methionine in the 66 position of BDNF protein). To the best of our knowledge, this is the only SNP with a reasonably known functional biological effect, the Met allele being associated with a decreased dendritic trafficking [69] . This functional polymorphism is assessed in 26 MDE samples. Some studies suggest an association between the Val66Met polymorphism and response or remission with antidepressant drugs, either in Asian [35, 48, 55] or in Caucasian [42, 46, 51, 59] patients. However, several studies failed to replicate this association, both in Asian [34, [38] [39] 45, 47, 53, 58, 60] and in Caucasian [37, 41, [43] [44] 49, 51, 54, 56, 61] patients, including the powerful study comprising the STAR-D results [44] . Meta-analyses [70] [71] [72] pointed out either a higher response rate in Met patients that may be specific to Asian patients, or no difference in response and remission rates between Met and Val/Val Caucasian patients. The meta-analysis of Niitsu et al., 2013 [73] including ten studies (eight of Asian patients [34] [35] 39, 45, 48, 50, 52, 74] ), one study of Caucasian patients [36] and data from STAR-D) showed that in Asian patients, the Met allele is associated with a higher anti depressant efficacy (level 2B). In Caucasian patients however, the Val66Met effect remains unclear. As the frequency of the Met66 allele is different between Caucasian (16-28%) and Asian (35-54%) populations, the functionality could be different in these populations. Moreover, some differences may exist between antidepressants. Licinio et al., 2009 [41] found no different effect between fluoxetine (n = 97) and desipramine (n = 103). However, Xu et al., 2012 [55] found a higher 4-week antidepressant efficacy in Met carriers treated with SSRI (n = 104) but not with venlafaxine (n = 55). In a recent study we reported [62] interactions between the Val66Met polymorphism and antidepressant drug classes: with SSRI, Val/Val patients had a higher response rate than Met patients. With SNRI/TCA, Val/Val patients had a lower remission rate than Met patients.
Other BDNF genetic polymorphisms For the other BDNF SNPs associated with antidepressant efficacy, to the best of our knowledge, there is no biological effect documented and none of these associations were replicated (level 3). For example, the rs2049046 polymorphism was assessed in one study and was associated with antidepressant efficacy (level 3) [56] , however, the promising effect of this polymorphism needs to be replicated in further studies.
Six SNPs are associated with antidepressant efficacy, but they were not replicated in other studies (level 3). [41] showed that the GG genotype was associated with a higher efficacy but this was not replicated by Illi et al., 2013 [57] (level 3). For rs7103411, the TT genotype was associated with a lower antidepressant efficacy [44] , but this result was not replicated in a second study [54] . For rs7124442 (a missense exonic mutation), the TT genotype was associated with a higher antidepressant efficacy [44] , but this result was not replicated in two other papers [41, 54] (level 3). For rs1491850 (5´-UTR), the C allele was associated with a higher antidepressant efficacy [49] , but this result was not replicated in a second study [56] (level 3). For rs908867 (5´-UTR), the A allele was associated with a higher antidepressant efficacy [37] , but this result was not replicated in two other studies [41, 49] . Finally the C allele of rs10501087 (3´-UTR) was associated with a higher antidepressant efficacy [49] but was also not replicated in a second study [37] (level 3).
BDNF haplotype analyses Table 3 shows results about BDNF haplotype analyses. Five haplotypes were associated with antidepressant efficacy.
TRKB polymorphisms
There were only three studies focusing on 153 TRKB SNPs (Table 1) . Only one study was a randomized double-blind controlled one [16] . In the two other studies, antidepressants were prescribed in open naturalist designs [56, 58] . They were short term (with a maximum of 12-week duration). The samples were heterogeneous regarding ethnicity (Mexican Americans [16] , Caucasians [56] and Asian [58] Polymorphisms with a reported association with antidepressant efficacy Table 4 shows the TRKB SNPs associated with antidepressant efficacy in at least one study, corresponding to a level of evidence of 3. None of these positive associations were replicated.
TRKB haplotype analysis
None of them reported TRKB haplotypes with a significant association (after correction for multiple tests) with antidepressant efficacy [16, 56] .
P75NTR polymorphisms
Despite preclinical evidence of the relevance of P75NTR in the BDNF/TRKB/P75NTR pathway, we found only one pharmacogenetic study assessing P75NTR impact on antidepressant efficacy in depressed patients [40] . BDNF/TRKB/P75NTR polymorphisms & their consequences on antidepressant efficacy in depressed patients Review in CC patients (p = 0.04). The constructed haplotype (rs2072446-rs11466155-rs734194) was associated with response, the TCT patients having a lower response to SSRI (p = 0.01). The non synonymous polymorphism may thus contribute to the functional alteration of p75NTR (T carriers). Moreover, other SNPs were described in the literature to have an impact on several conditions like asthma, migraine, Alzheimer disease (rs9908234, rs3785931, rs2072445, rs2072446, rs734194, rs741072, rs10491195) and could be assessed regarding antidepressant efficacy.
BDNF*TRKB polymorphism interactions
Only two studies investigated possible interactions between BDNF and TRKB on antidepressant efficacy. Hennings et al., 2013 [56] showed an interaction between the BDNF SNP rs4923468 and the NTRK2 SNP rs1387926. Li et al., 2013 [58] used an original method to explore interactions between three TRKB SNP (rs1387923-rs1565445-rs2769605) and one BDNF SNP (rs6265) and evidenced a 57.4% accuracy for the four-SNP model.
Discussion
Globally, there are 15 positive studies among 30 studies regarding BDNF/TRKB/P75NTR polymorphisms and their association with antidepressant efficacy in depressed patients. For BDNF polymorphisms, eight out of 47 (17%) polymorphisms studied seem to be significantly associated with antidepressant efficacy, of which three are intronic. The only, SNP which benefits of at least three positive studies is the BDNF Val66Met polymorphism (rs6265). The results show that the Met allele is associated with a higher antidepressant efficacy in Asian MDD patients (level of evidence 2B). Seven other polymorphisms may be also associated with antidepressant efficacy: rs1491850, rs10501087, rs61888800, rs7124442, rs7103411, rs908867 and rs2049046 but were not replicated. In positive studies, the effect sizes were small to moderate (OR comprised between: 1.88 and 4.85). Some evidence argues for a different impact of BDNF polymorphisms depending on antidepressant drugs. These data are in line with some preclinical ones. Met carrier mice responded to desipramine, a tricyclic antidepressant, but not to an SSRI [22] . However, clarifications about the influence of genetic variant BDNF on monoaminergic transporters would be useful. Indeed, the impact of the Met allele on 5-HTT expression or on the density of serotonergic neurons [75] was not replicated recently [76] . Furthermore, an increased BDNF protein expression in the frontal cortex was observed with SNRIs but not with SSRIs [23, 24] . Moreover, a chronic treatment with an SNRI, but not an SSRI, can reduce mature BDNF in the cytosol and increase its level in the crude synaptosomal fraction, suggesting that SNRIs, but not SSRIs, not only produce a marked upregulation of BDNF mRNA and protein, but may also affect the subcellular redistribution of the BDNF [23] .
Even if some studies in this field are negative [52, 53, 56] , further studies assessing serum BDNF as a possible proxy of central BDNF concentration and antidepressant efficacy may improve the understanding of the biological effect of these genetic polymorphisms.
For the TRKB four SNPs, rs11140778, rs10868223, rs1659412 and rs1565445, of which three are intronic were associated with a higher antidepressant efficacy, but none of these associations were replicated.
For the p75NTR gene, only one positive study is available (rs2072446).
In the absence of replication, the clinical and biological significance of these data is doubtful. However, these polymorphisms could be in linkage disequilibrium with others which could have relevant biological effects. Only one of them (BDNF rs2049046) was found to be in linkage disequilibrium with rs6265. So, it is probably not its effect but the effect of Val66Met which is observed here. For other intronic polymorphisms, different possible biological mechanisms to explain their association with antidepressant efficacy could be suggested, such as alternative splicing, transcription regulation, translation regulation or epigenetic changes.
Limitations
Some limitations exist in the field of genetic approaches. In GWAS, the high number of SNPs studied leads to increased significance level and decreased power. Indeed, these studies are designed to detect the effects of frequent SNPs. In the meta-analysis [68] , a satisfying power exists only for SNPs with allelic frequency at upper 0.25. However, the TRKB/BDNF/p75NTR SNPs associated with antidepressant efficacy have frequently lower minor allelic frequency. Some authors suggest that future GWAS should need samples of tens of thousands of patients rather than the thousands usually studied [77] . Additionally, the available genotyping platforms are able to provide only a relatively narrow genomic coverage (e.g., less than 50% in the STAR*D) [78] .
Some limitations exist in the field of methodology of clinical studies as well. The majority of studies are based on small and heterogeneous samples of patients. In terms of diagnoses, because MDD and bipolar disorder could be different in terms of antidepressant response, this heterogeneity in the samples studied could impact the results. Efficacy of antidepressant drugs may also differ between bipolar and unipolar patients. Moreover, there is a possible different impact of genetic polymorphisms with different types of antidepressant drugs. This point could be a confounding factor. Ethnicity or treatment duration should also be taken into account.
Another limitation is that the biological consequences of the SNPs are not well known in humans.
Last, but not least, publication biases are a major limitation of this review. Publication biases are frequent in the medical literature, positive studies being as much as three-times more likely to be published than negative studies [79] . This is a limitation of this review, in which the positive results could be overestimated as compared with the whole data obtained in this field [79] .
Future perspective
In terms of clinical perspectives, we recommend well characterized and homogenous phenotypes: either MDD or bipolar disorders, or both MDD and bipolar disorders with separate analyses. Accordingly, ethnicity should be precisely described, and if mixed ethnicity populations are included, they should be analyzed separately. We also recommend that further studies have longer than 3 months duration. The more frequently used designs are prospective naturalistic cohorts with blind genotype assessment. Actually, a placebo-controlled RCT to assess polymorphism effects on antidepressant efficacy is usually not performed for ethical reasons. Moreover, patients in RCT are quite selected and nonrepresentative of real-life patients. And, if positive results could be found in an RCT, these results would have to be confirmed in naturalistic designs to assess their clinical relevance in daily clinical practice. In this context, adding a randomization to a longitudinal open cohort, as did Licinio et al., 2009 [41] and Dong et al., 2009 [16] appears to be a good compromise.
In terms of genetic and biological perspectives, even if the expected effect size could be rather small, 37 BDNF SNPs described in the literature, not yet studied for antidepressant efficacy, should be studied, especially the three exonic missense SNPs, and the TRKB and p75NTR genes. Moreover, although BDNF/TRKB/PNTR75 interacts with the monoamine system which may affect the clinical response to antidepressants, the interaction between the BDNF/TRKB/ PNTR75 gene and genes related to the monoamine or glutamatergic systems on antidepressant efficacy should be studied.
Biological indices such as BDNF serum, LCR BDNF or brain imaging markers could also be helpful to better understand the role of SNPs on antidepres-future science group BDNF/TRKB/P75NTR polymorphisms & their consequences on antidepressant efficacy in depressed patients Review sant efficacy. BDNF expression which is also regulated by epigenetic chromatin remodeling, including DNA methylation, histone acetylation and other chemical alterations in gene promoter regions should also be studied, since an increase in CpG methylation at promoter regions on the BDNF gene was correlated with decreased synthesis of BDNF in neurons [80] .
Moreover, the involvement of common functional variants in antidepressants drug response, specifically of brain methylations sites, was described recently by Wong et al., 2014 [81] . Interestingly, those results support some previous works on the influence of variation in DNA methylation. Indeed, in the CNS, DNA methylation of cytosines in cytosine-guanine (CpG) dinucleotides is regarded as the representative component of broader epigenetic modification at a given locus [82] , and suggesting that the consequence of those epigenetic markers could be more investigated, particularly during pregnancy [83] , and human studies developmentally sensitive to the quality of the environment [84, 85] .
However, as with other psychiatric disorders, the genetics of MDD and antidepressant efficacy is complex. Genetic risk factors with individually large effects are likely to rare. Association-based methods to identify common genetic risk alleles in MDD presented limited success. Genome-wide association studies based on common genetic variants have yielded relatively few candidate genes that are not confirmed by replication. Alternative approaches that focus on rare genetic variants are needed. One genetic approach that was used effectively to overcome some problems of heterogeneity is the genome-wide analysis of copy-number variants (CNVs). Current geno typing platforms and CNV discovery algorithms enable the genotyping of copy number polymorphisms and the analysis of CNVs. CNVs are submicroscopic deletions and duplications in genomic DNA that were implicated in a variety of different psychiatric disorders. Interestingly, studies from multiple groups have now firmly established that rare CNVs contribute to genetic risk for schizophrenia, autism spectrum disorder, MDD and, in particular, that spontaneous CNVs are important risk factors in the sporadic form of the disorders [86] [87] [88] [89] . Morever, recently, Tansey et al., 2014 [90] found that specific CNVs were nominally associated with poor response to antidepressants in MDD patients.
One of the most interesting as well as challenging observations has been the degree of phenotypic variability associated with individual CNVs, in other words, the 'expressivity' of the genotype. Undoubtedly, the phenotypic expression of rare high penetrance alleles is modulated by other genetic factors, including rare variants, as well as common (polygenic) variation [91] or epigenetic regulation [81, 92] .
Executive summary
Preclinical data
• BDNF/TRKB/pNTR75 are involved in antidepressant efficacy.
BDNF genetic polymorphisms
• The Met allele of the Val66Met polymorphism is associated with a higher antidepressant efficacy in Asian major depressive disorder patients (good level of evidence).
• Seven other polymorphisms (rs7103411, rs7124442, rs908867, rs2049046, rs61888800, rs10501087 and rs1491850) may also be associated with antidepressant efficacy, but no replication is available.
TRKB genetic polymorphisms
• Four polymorphisms (rs11140778, rs10868223, rs1659412 and rs1565445) may be associated with antidepressant efficacy, but no replication is available.
P75NTR genetic polymorphisms
• One polymorphism (rs2072446) may be associated with antidepressant efficacy.
Future perspective
• Further studies are needed since several SNP of BDNF/TRKB/P75NTR have never been explored.
• For further clinical studies, we recommend to separately analyze major depressive disorders and bipolar disorders.
• Different impacts of BDNF polymorphisms between different antidepressant drugs need to be better assessed, eventually as a primary objective of further clinical studies.
• Composite scores using gene*gene interaction or gene*biomarker interaction may help to predict antidepressant efficacy.
Conclusion
• Finally, there are 15 positive studies among 30 studies regarding BDNF/TRKB/P75NTR polymorphisms. The only SNP which benefits of at least three positive studies is the BDNF Val66Met polymorphism (rs6265).
• Consequently, with a lack of good and consistent studies, the clinical utility of BDNF in treatment selection is far from clear.
Since the effects of SNPs alone may be rather limited, integration of several biomarkers could be relevant. And composite scores using gene*gene interaction or gene*biomarker interaction could be useful to predict antidepressant efficacy.
Finally, there are 15 positive studies among 30 studies regarding BDNF/TRKB/P75NTR poly morphisms and their association with antidepressant efficacy in depressed patients. The only, SNP which benefits of at least three positive studies is the BDNF Val66Met polymorphism (rs6265). Moreover, studies suffer from methodological limitations. Consequently, with a lack of good and consistent studies, the clinical utility of BDNF in treatment selection is far from clear. No writing assistance was utilized in the production of this manuscript.
